medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2021, Number 2

<< Back Next >>

Medicina & Laboratorio 2021; 25 (2)

Human papillomavirus (HPV) and cancer

Toro-Montoya AI, Tapia-Vela LJ

Language: Spanish
References: 56
Page: 467-483
PDF size: 321.56 Kb.


ABSTRACT

Each year, more than half a million women in the world are diagnosed with cervical cancer, usually associated with high-risk human papillomavirus (HPV) infection. Although most HPV infections resolve within 2 years, some viral types, particularly HPV16, can persist for decades and cause different types of cancer, being the cervical type the most common. The natural history of high-risk HPV infection and the prolonged period in which its progression occurs, allows for the prevention of the disease. High-risk HPV infection that progresses to cancer includes several processes such as viral genome integration, uncontrolled cell division, and the participation of cellular and epigenetic changes. The conventional Pap smear test that has been practiced as a screening method for more than 50 years continues to be used, especially in low- and middle-income countries, but it is being replaced by other methods such as molecular tests that directly detect the presence of the virus, with greater effectiveness as a screening test. In 2014, the Ministry of Health and Social Protection of Colombia developed a clinical practice guide for the detection and management of premalignant cervical lesions, in which the DNA-HPV test is recommended for initial screening in women over 30 years. So far, positive results have been found with the implementation of the test, however, additional studies are required to confirm these findings given its importance in controlling the morbidity and mortality associated with the infection.


REFERENCES

  1. de Sanjosé S, Brotons M, Pavón MA. The naturalhistory of human papillomavirus infection. BestPract Res Clin Obstet Gynaecol 2018;47:2-13.https://doi.org/10.1016/j.bpobgyn.2017.08.015.

  2. Okunade KS. Human papillomavirus and cervicalcancer. J Obstet Gynaecol 2020;40:602-608. https://doi.org/10.1080/01443615.2019.1634030.

  3. Chan CK, Aimagambetova G, Ukybassova T,Kongrtay K, Azizan A. Human papillomavirusinfection and cervical cancer: Epidemiology,screening, and vaccination-review of currentperspectives. J Oncol 2019;2019:3257939.https://doi.org/10.1155/2019/3257939.

  4. Schiffman M, Doorbar J, Wentzensen N, deSanjosé S, Fakhry C, Monk BJ, et al. Carcinogenichuman papillomavirus infection. NatRev Dis Primers 2016;2:16086. https://doi.org/10.1038/nrdp.2016.86.

  5. Cai T, Di Vico T, Durante J, Tognarelli A,Bartoletti R. Human papilloma virus and genitourinarycancers: a narrative review. MinervaUrol Nefrol 2018;70:579-587. https://doi.org/10.23736/s0393-2249.18.03141-7.

  6. Gilbert DC, Wakeham K, Langley RE, ValeCL. Increased risk of second cancers at sitesassociated with HPV after a prior HPV-associatedmalignancy, a systematic review andmeta-analysis. Br J Cancer 2019;120:256-268.https://doi.org/10.1038/s41416-018-0273-9.

  7. Toro-Montoya AI, Piedrahita-Ochoa C, Gallego-Noreña G. Tamización y prevención del cáncercervical causado por papilomavirus. Med Lab2010;16:511-546.

  8. Moscicki A-B, Schiffman M, Franceschi S. Chapter

  9. 9 - The natural history of human papillomavirusinfection in relation to cervical cancer. In:Jenkins D, Bosch FX, eds. Human Papillomavirus:Academic Press; 2020. p. 149-160. https://doi.org/10.1016/B978-0-12-814457-2.00009-X.9. Piña-Napal JC, Crespo-Campos G, Fando-Calzado R, Casanova-Corona G, Curbelo-ToledoM, Guerra-Rodríguez MM. Identificaciónmolecular de genotipos papilomavirus humanosen pacientes con cáncer de cuello uterino.AMC 2016;20:288-298.

  10. Pérez-Pérez N, Tedesco S, González F, JordiJML, Rey G. Prevalencia de los genotipos deHPV en lesiones pre invasoras de alto grado demalignidad y cáncer de cuello uterino en la poblacióndel Hospital de Clínicas. Montevideo-Uruguay. Anfamed 2020;7:e202.

  11. World Health Organization (WHO). Humanpapillomavirus (HPV) and cervical cancer. Factsheets. Ginebra, Suiza: World Health Organization;2020. Acceso 15 de febrero de 2020. Disponibleen https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer.

  12. Vorsters A, Bosch FX, Bonanni P, Franco EL,Baay M, Simas C, et al. Prevention and controlof HPV infection and HPV-related cancers in Colombia-a meeting report. BMC Proc 2020;14:8.https://doi.org/10.1186/s12919-020-00192-2.

  13. Bzhalava D, Eklund C, Dillner J. Internationalstandardization and classification of human papillomavirustypes. Virology 2015;476:341-344.https://doi.org/10.1016/j.virol.2014.12.028.

  14. Woodman CB, Collins SI, Young LS. The naturalhistory of cervical HPV infection: unresolvedissues. Nat Rev Cancer 2007;7:11-22. https://doi.org/10.1038/nrc2050.

  15. Albert E, Laimins L. Regulation of the humanpapillomavirus life cycle by DNA damagerepair pathways and epigenetic factors. Viruses2020;12:744. https://doi.org/10.3390/v12070744.

  16. Bordignon V, Di Domenico EG, Trento E,D'Agosto G, Cavallo I, Pontone M, et al. Howhuman papillomavirus replication and immuneevasion strategies take advantage of the host DNAdamage repair machinery. Viruses 2017;9:390.https://doi.org/10.3390/v9120390.

  17. Smola S. Immunopathogenesis of HPV-AssociatedCancers and Prospects for Immunotherapy.Viruses 2017;9:254. https://doi.org/10.3390/v9090254.

  18. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervicalcancer. Lancet 2019;393:169-182. https://doi.org/10.1016/s0140-6736(18)32470-x.

  19. de Sanjosé S, Diaz M, Castellsagué X, CliffordG, Bruni L, Muñoz N, et al. Worldwide prevalenceand genotype distribution of cervical human papillomavirusDNA in women with normal cytology:a meta-analysis. Lancet Infect Dis 2007;7:453-459.https://doi.org/10.1016/s1473-3099(07)70158-5.

  20. Sichero L, Picconi MA, Villa LL. The contributionof Latin American research to HPV epidemiologyand natural history knowledge. BrazJ Med Biol Res 2020;53:e9560. https://doi.org/10.1590/1414-431x20199560.

  21. Moya-Salazar JJ, Rojas-Zumaran V. Tendenciasen la investigación del virus de papiloma humanoen Latinoamérica frente a los países de altos ingresos.Rev Colomb Obstet Ginecol 2017;68:202-217. https://doi.org/10.18597/rcog.2679.

  22. Sequera M, Matamoros A, León M. Genotiposde VPH y cambios citológicos cervico-uterino enpacientes de una consulta ginecológica privadadel Estado Carabobo, Venezuela. Marzo-octubrede 2017. Rev Med Risaralda 2020;26:28-37.https://doi.org/10.22517/25395203.20781.

  23. Bobadilla ML, Villagra V, Zorrilla ME, Pablo P,Olmedo G, Roscher G, et al. Detección moleculardel papilomavirus humano de alto riesgoen el seguimiento de mujeres tratadas por lesiónescamosa intraepitelial. Mem Inst InvestigCienc Salud 2016;14:64-69.

  24. Ochoa-Carrillo FJ, Guarneros de Regil DB,Velasco-Jiménez MT. Infección por virus delpapiloma humano en mujeres y su prevención.GAMO 2015;14:157-163. https://doi.org/10.1016/j.gamo.2015.08.002.

  25. Petca A, Borislavschi A, Zvanca ME, Petca RC,Sandru F, Dumitrascu MC. Non-sexual HPVtransmission and role of vaccination for a betterfuture (Review). Exp Ther Med 2020;20:186.https://doi.org/10.3892/etm.2020.9316.

  26. Gravitt PE, Winer RL. Natural history of HPV infectionacross the lifespan: Role of viral latency.Viruses 2017;9:267. https://doi.org/10.3390/v9100267.

  27. Bruni L AG, Serrano B, Mena M, Gómez D, MuñozJ, Bosch FX, et al. Human Papillomavirusand RelatedDiseases in the World. Barcelona, España:ICO/IARC Information Centre on HPV andCancer (HPV Information Centre); 2019. Acceso21 de febrero de 2021. Disponible en https://hpvcentre.net/statistics/reports/XWX.pdf.

  28. Engelsgjerd JS, LaGrange CA. Penile Cancer.Treasure Island (FL): StatPearls Publishing;2021. Acceso 14 de febrero de 2021. Disponibleen https://www.ncbi.nlm.nih.gov/books/NBK499930/.

  29. Aranda-Flores CE. Infección por virus del papilomahumano: historia natural del cáncer depene. GAMO 2016;15:323-326. https://doi.org/10.1016/j.gamo.2015.12.011.

  30. Iorga L, Dragos-Marcu R, Cristina-DiaconuC, Alexandra-Stanescu A, Pantea-StoianA, Dorel-Mischianu D, et al. Penile carcinomaand HPV infection (Review). Exp TherMed 2020;20:91-96. https://doi.org/10.3892/etm.2019.8181.

  31. Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett TR, Cheung L, Chen X, et al. Astudy of type-specific HPV natural history andimplications for contemporary cervical cancerscreening programs. EClinicalMedicine2020;22:100293. https://doi.org/10.1016/j.eclinm.2020.100293.

  32. Saslow D, Solomon D, Lawson HW, KillackeyM, Kulasingam SL, Cain J, et al. AmericanCancer Society, American Society for Colposcopyand Cervical Pathology, and AmericanSociety for Clinical Pathology screening guidelinesfor the prevention and early detection ofcervical cancer. CA Cancer J Clin 2012;62:147-172. https://doi.org/10.3322/caac.21139.

  33. Johnson DE, Burtness B, Leemans CR, LuiVWY, Bauman JE, Grandis JR. Head and necksquamous cell carcinoma. Nat Rev Dis Primers2020;6:92. https://doi.org/10.1038/s41572-020-00224-3.

  34. Fudulu A, Albulescu A, Anton G. Human papillomaviruses'proteins with clinical utility. JImmunoassay Immunochem 2019;40:81-90.https://doi.org/10.1080/15321819.2018.1553790.

  35. White EA, Kramer RE, Tan MJ, Hayes SD, HarperJW, Howley PM. Comprehensive analysisof host cellular interactions with human papillomavirusE6 proteins identifies new E6 bindingpartners and reflects viral diversity. J Virol2012;86:13174-13186. https://doi.org/10.1128/jvi.02172-12.

  36. Neveu G, Cassonnet P, Vidalain PO, Rolloy C,Mendoza J, Jones L, et al. Comparative analysisof virus-host interactomes with a mammalianhigh-throughput protein complementation assaybased on Gaussia princeps luciferase. Methods2012;58:349-359. https://doi.org/10.1016/j.ymeth.2012.07.029.

  37. Pattyn J, Van Keer S, Tjalma W, MatheeussenV, Van Damme P, Vorsters A. Infection andvaccine-induced HPV-specific antibodies in cervicovaginalsecretions. A review of the literature.Papillomavirus Res 2019;8:100185. https://doi.org/10.1016/j.pvr.2019.100185.

  38. Bhatla N, Singhal S. Primary HPV screening forcervical cancer. Best Pract Res Clin Obstet Gynaecol2020;65:98-108. https://doi.org/10.1016/j.bpobgyn.2020.02.008.

  39. Guido R. Cervical Cancer Screening. ClinObstet Gynecol 2018;61:40-51. https://doi.org/10.1097/grf.0000000000000336.

  40. Lagheden C, Eklund C, Lamin H, Kleppe SN,Lei J, Elfström KM, et al. Nationwide comprehensivehuman papillomavirus (HPV) genotypingof invasive cervical cancer. Br J Cancer2018;118:1377-1381. https://doi.org/10.1038/s41416-018-0053-6.

  41. Ronco G, Dillner J, Elfström KM, Tunesi S, SnijdersPJ, Arbyn M, et al. Efficacy of HPV-basedscreening for prevention of invasive cervical cancer:follow-up of four European randomised controlledtrials. Lancet 2014;383:524-532. https://doi.org/10.1016/s0140-6736(13)62218-7.

  42. Arbyn M, Ronco G, Anttila A, Meijer CJ, PoljakM, Ogilvie G, et al. Evidence regardinghuman papillomavirus testing in secondaryprevention of cervical cancer. Vaccine 2012;30Suppl 5:F88-99. https://doi.org/10.1016/j.vaccine.2012.06.095.

  43. Curry SJ, Krist AH, Owens DK, Barry MJ,Caughey AB, Davidson KW, et al. Screeningfor cervical cancer: US Preventive ServicesTask Force recommendation statement. Jama2018;320:674-686. https://doi.org/10.1001/jama.2018.10897.

  44. Ministerio de Salud y Protección Social, InstitutoNacional de Cancerología-ESE. Guía dePráctica Clínica para la detección y manejo delesiones precancerosas de cuello uterino. GuíaNo. 44. Bogotá D.C.: Ministerio de Salud y ProtecciónSocial; 2014 Acceso 03 de febrero de2021. Disponible en https://www.cancer.gov.co/Gu%C3%ADas-y-Protocolos/Gu%C3%ADas-de-Practica-clinica/LPC-Guia-profesionales.pdf.

  45. Arbeláez-Vásquez A, Carreño C, Coñazos-RamírezL, Castillo A. Implementación de la nueva guíapráctica clínica para la detección y manejo de lesionesprecancerosas de cuello uterino en mujeres dela ciudad de Cali, Colombia. Infectio 2020;24:20-26.

  46. PDQ Screening and Prevention EditorialBoard. Cervical cancer screening (PDQ®):Health professional version. PDQ cancer informationsummaries. Bethesda (MD): NationalCancer Institute (US); 2020 Acceso 17 de feberode 2021. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK65734/?report=classic.

  47. Gage JC, Hanson VW, Abbey K, Dippery S,Gardner S, Kubota J, et al. Number of cervicalbiopsies and sensitivity of colposcopy.Obstet Gynecol 2006;108:264-272. https://doi.org/10.1097/01.Aog.0000220505.18525.85.

  48. Pretorius RG, Zhang WH, Belinson JL, HuangMN, Wu LY, Zhang X, et al. Colposcopicallydirected biopsy, random cervical biopsy, andendocervical curettage in the diagnosis of cervicalintraepithelial neoplasia II or worse. Am JObstet Gynecol 2004;191:430-434. https://doi.org/10.1016/j.ajog.2004.02.065.

  49. Wentzensen N, Walker JL, Gold MA, SmithKM, Zuna RE, Mathews C, et al. Multiple biopsiesand detection of cervical cancer precursorsat colposcopy. J Clin Oncol 2015;33:83-89.https://doi.org/10.1200/jco.2014.55.9948.

  50. Kelly R, Walker P, Kitchener H, Moss S. Incidenceof cervical intraepithelial neoplasia grade 2 orworse in colposcopy-negative/human papillomavirus-positive women with low-grade cytologicalabnormalities. BJOG 2012;119:20-25. https://doi.org/10.1111/j.1471-0528.2011.02970.x.

  51. Massad LS, Jeronimo J, Katki HA, Schiffman M.The accuracy of colposcopic grading for detectionof high-grade cervical intraepithelial neoplasia. JLow Genit Tract Dis 2009;13:137-144. https://doi.org/10.1097/LGT.0b013e31819308d4.

  52. Nogueira-Rodrigues A. HPV vaccination in LatinAmerica: Global challenges and feasible solutions.Am Soc Clin Oncol Educ Book 2019;39:e45-e52. https://doi.org/10.1200/edbk_249695.

  53. Strategic Advisory Group of Experts on immunization.Meeting of the Strategic AdvisoryGroup of Experts on immunization, April 2014:Conclusions and recommendations. Wkly EpidemiolRec 2014;89:221-236.

  54. Gómez-Muñoz JM, Gómez-Rincón JC, Alí-Munive A, Cano-Gutiérrez CA, Coral-AlvaradoPX, Coronell-Rodríguez W, et al. Guíaspara la inmunización del adolescente y adultoen Colombia. Documento de actualización,2016. Infectio 2016;20:192-210. https://doi.org/10.1016/j.infect.2016.08.001.

  55. Ministerio de Salud y Protección Social.Vacunación contra el Virus Papiloma humano- VPH en Colombia, para la prevención delcáncer de cuello uterino y verrugas genitales.2012. Acceso 11 de febrero de 2021. Disponibleen https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/IA/INCA/1-vacunacion-contra-virus-papiloma%20humanoverrugas-genitales.pdf.

  56. Instituto Nacional de Cancerología-ESE. Evidenciasobre la seguridad de la vacuna contrael cáncer de cuello uterino. Bogotá D.C.: InstitutoNacional de Cancerología-ESE; 2018.Acceso 06 de febrero de 2021. Disponible enhttps://www.cancer.gov.co/files/libros/archivos/Evdencia%20sobre%20la.




2020     |     www.medigraphic.com